| __timestamp | Neurocrine Biosciences, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 40786000 |
| Thursday, January 1, 2015 | 32480000 | 47876000 |
| Friday, January 1, 2016 | 68081000 | 52035000 |
| Sunday, January 1, 2017 | 169906000 | 55348000 |
| Monday, January 1, 2018 | 248932000 | 65276000 |
| Tuesday, January 1, 2019 | 354100000 | 82720000 |
| Wednesday, January 1, 2020 | 433300000 | 89118000 |
| Friday, January 1, 2021 | 583300000 | 181193000 |
| Saturday, January 1, 2022 | 752700000 | 174078000 |
| Sunday, January 1, 2023 | 887600000 | 184232000 |
| Monday, January 1, 2024 | 1007200000 |
In pursuit of knowledge
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. Over the past decade, Neurocrine Biosciences, Inc. and Veracyte, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine Biosciences saw a staggering 4,800% increase in SG&A expenses, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Veracyte, Inc. experienced a more modest 350% rise, indicating a more conservative approach to scaling operations.
By 2023, Neurocrine's SG&A expenses were nearly five times higher than Veracyte's, highlighting divergent strategies in managing operational costs. This data provides a fascinating insight into how two companies navigate the financial demands of the biotech industry, offering valuable lessons in balancing growth with fiscal responsibility.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Sanofi vs Veracyte, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Zoetis Inc. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: GSK plc vs Veracyte, Inc.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Dr. Reddy's Laboratories Limited
Neurocrine Biosciences, Inc. vs Exelixis, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Evotec SE
Operational Costs Compared: SG&A Analysis of Ionis Pharmaceuticals, Inc. and Veracyte, Inc.